No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: Results of a randomized double-blind placebo-controlled cross-over study

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 2, 2001, Pages 171-175

  Vleggaar, Frank P ^a   Van Buuren, Henk R ^a   Van Berge Henegouwen, Gerard P ^b   Hop, Wim C J ^c   Van Erpecum, Karel J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Primary sclerosing cholangitis; Transdermal nicotine; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE SALT; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; NICOTINE GUM; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; HUMAN; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; SMOKING; ULCERATIVE COLITIS; WEIGHT GAIN;

ADMINISTRATION, CUTANEOUS; ADULT; BIOLOGICAL MARKERS; CHOLANGITIS, SCLEROSING; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; URSODEOXYCHOLIC ACID;

EID: 0035131698     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200102000-00013     Document Type: Article

References (28)

1. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332: 924-933.
2. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A. et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-615.
3. Shepherd HA, Selby WS, Chapman RW, Nolan D, Barbatis C, McGee JO. et al. Ulcerative colitis and persistent liver dysfunction. Q J Med 1983; 52: 503-513.
4. Schrumpf E, Fausa O, Elgjo K, Kolmannskog F. Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis 1988; 8: 201-209.
5. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988; 95: 1036-1042.
6. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994; 106: 494-499.
7. Hoogstraten HJF, van Vleggaar FP, Boland GJ, Steenbergen W, van Griffioen P, Hop WCJ. et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double blind pilot study. Am J Gastroenterol 2000; 95: 2015-2022.
8. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W. et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16: 707-714.
9. Van Hoogstraten HJF, Wolfhagen FHJ, van de Meeberg PC, Kuiper H, Nix GAJJ, Becx MCJM. et al. Ursodeoxycholic acid for primary sclerosing cholangitis: results of a 2-year randomized controlled trial evaluating single versus multiple daily doses. J Hepatol 1998; 29: 417-423.
10. Lindor KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997; 336: 691-695.
11. Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis [Letter]. Br Med J 1982; 284: 706.
12. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT. et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330: 811-815.
13. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP. et al. Transdermal nicotine for mildly to moderately active ulcerative colitis.: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 364-371.
14. Madretsma GS, Wolters LMM, van Dijk JPM, Tak CJAM, Feyerabend C, Wilson JHP. et al. In vivo effect of nicotine on cytokine production by human non-adherent mononuclear cells. Eur J Gastroenterol Hepatol 1996; 8: 1017-1020.
15. Loftus EV Jr, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP. et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996; 110: 1496-1502.
16. Van Erpecum KJ, Smits SJ, van de Meeberg PC, Linn FH, Wolfhagen FH, van Berge-Henegouwen GP. et al. Risk of primary sclerosing cholangitis is associated with nonsmoking behaviour. Gastroenterology 1996; 110: 1503-1506.
17. Mitchell SA, Thyssen M, Mitchell M, Orchard TR, Jewell DP, Fleming KA. et al. Cigarette smoking, appendectomy and tonsillectomy as risk factors for the development of primary sclerosing cholangitis (PSC): a case control study [Abstract]. Hepatology 1998; 28: 446A.
18. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Br Med J 1955; 2: 1041-1048.
19. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
20. MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983; 149: 39-44.
21. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979; 8: 7-20.
22. Angulo P, Bharucha AE, Jorgensen RA, DeSotel CK, Sandborn WJ, LaRusso NF. et al. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci 1999; 44: 602-607.
23. Jorenby DE, Hatsukami DK, Smith SS, Fiore MC, Allen S, Jensen J. et al. Characterisation of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. Psychopharmacology 1996; 128: 130-138.
24. Perkins KA, Epstein LH, Stiller RL, Fernstrom MH, Sexton JE, Jacob RG. et al. Acute effects of nicotine on hunger and caloric intake in smokers and nonsmokers. Psychopharmacology 1991; 103: 103-109.
25. Cohen RD, Hanauer SB. Protection from primary sclerosing cholangitis: smoke trails of just coattails? Gastroenterology 1996; 110: 1658-1662.
26. O’Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991; 14: 838-847.
27. Chazouilleres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M. et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990; 11: 120-123.
28. Lindor KD, Jorgensen RA, Anderson ML, Gores GJ, Hofmann AF, LaRusso NF. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 1996; 91: 511-515.